40 results about "Influenza virus RNA" patented technology

The present invention relates to soluble fragments of the Influenza virus RNA dependent RNA polymerase subunit PB2 and variants thereof, and crystallized complexes thereof comprising an RNA cap analog. This invention also relates to computational methods using the structural coordinates of said complex to screen for and design compounds that interact with the RNA cap binding pocket. In addition, this invention relates to methods identifying compounds that bind to PB2 polypeptide fragments comprising the RNA cap binding pocket, preferably inhibit the interaction with RNA caps or analogs thereof, by using said PB2 polypeptide fragments, preferably in a high-throughput setting. This invention also relates to compounds and pharmaceutical compositions comprising the identified compounds for the treatment of disease conditions due to viral infections caused by negative-sense single stranded RNA viruses.

The invention discloses a novel application of a caffeoylquinic acid compound. The novel application of caffeoylquinic acid compound provided in the invention shown in a formula I is an application of being as an influenza virus RNA polymerase inhibitor on one hand; on the other hand, the novel application of caffeoylquinic acid compound is an application of preparing the medicament for preventing and / or treating the diseases relative to the influenza virus RNA polymerase, especially relates to an application of preparing the medicament in resisting influenza virus, more especially relates toan application of preparing the medicament in resisting bird flu virus (H5N1).

The present invention provides the application of salvianolic acid B in the preparation of medicines for preventing or treating H5N1 influenza virus, wherein the salvianolic acid B has the following structural formula: salvianolic acid B can effectively inhibit the RNA polymerase subunit of H5N1 influenza virus Activity of PAN protein.

The invention provides an antiviral pharmaceutical molecule capable of inhibiting the activity of influenza virus RNA polymerase. An antiviral drug contains the structure represented by the followingformula 1, or the antiviral drug contains a compound with the structure represented by the formula 1 as a drug precursor.

The invention provides a combined nucleic acid real-time fluorescent detection method for simultaneously detecting an influenza A H1N1 virus and an influenza A virus and a kit. The combined nucleic acid real-time fluorescent detection method for the influenza A H1N1 virus and the influenza A virus comprises the following steps of: (1) extracting virus RNA; (2) carrying out fluorescent quantitative PCR (Polymerase Chain Reaction) detection; and (3) judging a detecting result. By carrying out multiple sequence comparison and aiming at a conserved gene fragment of the influenza A virus and the influenza A H1N1 virus (infecting in 2009), a primer and a probe with high specificity are designed and used for real-time fluorescent RT-PCR (Reverse Transcription-Polymerase Chain Reaction) detection. The invention can be used for detecting influenza A virus RNA of human influenza, swine influenza, avian influenza, and other influenza viruses, meanwhile specifically detecting the influenza A H1N1virus (infecting in 2009) RNA and carrying out double analysis so that a detecting result is more reliable.

The invention provides a method for detecting fowl influenza virus and parting primer system and augmenting fowl influenza virus RNA asymmetrically. The invention designs and screens 25 pairs multiple asymmetrical RT-PCR primers, a pair general primer, 52 specific probes and 3 quality control probes according to the report fowl influenza virus total hypotype genome sequence in Genebank, wherein every pair in 25 pairs multiple asymmetrical RT-PCR primers is fit for a hypotype of fowl influenza virus, the primer system comprising 25 pairs multiple asymmetrical RT-PCR primers and a pair general primer can be used for detecting and parting fowl influenza virus, the primer system builds the method of asymmetrically augmenting fowl influenza virus RNA and detecting and parting fowl influenza virus. The invention provides strong specificity, high sensibility, which also proceeds the first step application.

The invention discloses a subtype detection method of influenza A virus, which comprises the following steps: Step 1, designing and synthesizing primers; Step 2, preparing carboxyl magnetic beads connected with magnetic beads and forward primers; Step 3, A Influenza virus RNA extraction; Step 4, RT‑PCR; Step 5, magnetic adsorption and washing; Step 6, detection. The influenza A virus subtype detection method of the present invention can perform high-throughput, rapid, sensitive and specific typing of the influenza A virus subtype, and has good application value.

The invention discloses an influenza virus RNA polymerase purifying or crystallizing method. The influenza virus RNA polymerase crystallizing method comprises the following steps: co-expressing and purifying PB1 subunit encoding gene and PA subunit encoding gene of influenza virus RNA polymerase and encoding gene of PB2 subunit truncation in insect cells to obtain RNA polymerase, combining the RNA polymerase with RNA to form a complex, and crystallizing the complex to obtain influenza virus RNA polymerase crystals, wherein the PB2 subunit truncation is a protein formed by amino acid residues from N end to 126th position in a PB2 subunit amino acid sequence. Experiments prove that after different PB2 subunit truncations are used, the expression level of the influenza virus polymerase complex containing the 126 amino acid fragments of the amino end of PB2 is high, and 10mg of the protein can be purified through 1L of an insect cell culture solution, so the expression level of the influenza virus polymerase complex containing the 126 amino acid fragments of the amino end of PB2 is higher than that of other truncations; and the crystals obtained in the invention have the advantages of good purity, slight degradation, good crystallization repeatability, good quality, large size and strong diffraction.